Stephens Inc. AR Has $6.02 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Stephens Inc. AR boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 43.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 89,140 shares of the biopharmaceutical company’s stock after acquiring an additional 27,162 shares during the period. Stephens Inc. AR’s holdings in Gilead Sciences were worth $6,022,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Cooper Financial Group grew its holdings in Gilead Sciences by 4.3% in the 2nd quarter. Cooper Financial Group now owns 3,604 shares of the biopharmaceutical company’s stock worth $243,000 after acquiring an additional 149 shares during the last quarter. Lenox Wealth Management Inc. grew its holdings in shares of Gilead Sciences by 1.8% in the 1st quarter. Lenox Wealth Management Inc. now owns 9,059 shares of the biopharmaceutical company’s stock worth $589,000 after acquiring an additional 156 shares during the last quarter. Alpha Cubed Investments LLC grew its holdings in shares of Gilead Sciences by 0.6% in the 2nd quarter. Alpha Cubed Investments LLC now owns 25,592 shares of the biopharmaceutical company’s stock worth $1,729,000 after acquiring an additional 156 shares during the last quarter. Creative Financial Designs Inc. ADV grew its holdings in shares of Gilead Sciences by 55.9% in the 1st quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 165 shares during the last quarter. Finally, Blume Capital Management Inc. grew its holdings in shares of Gilead Sciences by 4.8% in the 2nd quarter. Blume Capital Management Inc. now owns 3,615 shares of the biopharmaceutical company’s stock worth $244,000 after acquiring an additional 165 shares during the last quarter. Hedge funds and other institutional investors own 78.87% of the company’s stock.

NASDAQ:GILD traded up $0.63 during trading hours on Thursday, hitting $63.75. 1,607,641 shares of the stock were exchanged, compared to its average volume of 6,220,770. The company’s 50 day moving average is $66.33. Gilead Sciences, Inc. has a twelve month low of $60.32 and a twelve month high of $79.61. The company has a debt-to-equity ratio of 1.13, a current ratio of 3.76 and a quick ratio of 3.67. The firm has a market capitalization of $81.03 billion, a P/E ratio of 10.37, a P/E/G ratio of 3.04 and a beta of 1.16.



Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.68 by $0.14. The company had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.54 billion. Gilead Sciences had a return on equity of 37.12% and a net margin of 26.64%. The firm’s quarterly revenue was down 2.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.91 EPS. On average, research analysts anticipate that Gilead Sciences, Inc. will post 6.65 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 3.95%. The ex-dividend date of this dividend is Thursday, September 12th. Gilead Sciences’s dividend payout ratio (DPR) is presently 40.98%.

A number of analysts have weighed in on the company. Cowen reaffirmed a “buy” rating on shares of Gilead Sciences in a research report on Friday, May 3rd. Royal Bank of Canada upgraded Gilead Sciences from an “outperform” rating to a “top pick” rating and set a $91.00 price target on the stock in a research note on Monday, July 29th. JPMorgan Chase & Co. restated a “buy” rating and set a $85.00 price target on shares of Gilead Sciences in a research note on Wednesday, July 31st. ValuEngine upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Morgan Stanley set a $82.00 price target on Gilead Sciences and gave the company a “hold” rating in a research note on Monday, July 15th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $82.29.

In related news, EVP Brett A. Pletcher sold 7,200 shares of the business’s stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $65.07, for a total transaction of $468,504.00. Following the completion of the sale, the executive vice president now directly owns 34,398 shares in the company, valued at $2,238,277.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Brett A. Pletcher sold 5,816 shares of the business’s stock in a transaction that occurred on Tuesday, June 18th. The shares were sold at an average price of $68.75, for a total transaction of $399,850.00. Following the sale, the executive vice president now owns 27,198 shares of the company’s stock, valued at $1,869,862.50. The disclosure for this sale can be found here. 0.20% of the stock is owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Read More: Special Dividends

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.